New targeted pill shows promise for Hard-to-Treat bile duct cancers
Disease control
Completed
This study tested a new oral drug called RLY-4008 in 490 adults with advanced bile duct cancer or other solid tumors that have specific FGFR2 gene changes. The drug is designed to block the FGFR2 protein, which can drive cancer growth. The trial aimed to find the safest dose and …
Phase: PHASE1, PHASE2 • Sponsor: Elevar Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC